Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Whitehawk Therapeutics, Inc.WHWK · Entity 6074 | Director | June 12, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Whitehawk Therapeutics, Inc.
Report date June 12, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.16 · Expires 2036-06-12 | Direct | 38,040 |
Reported balance
After 2026-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 38,040 · Balance 38,040 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MEDIVATION, INC.
Report date September 28, 2016 · Filed September 30, 2016
Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2016-09-28 · Other · Disposed 39,068 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Includes 229 shares purchased through the Issuer's Employee Stock Purchase Plan on September 21, 2016. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2016-09-28 · Disposition to issuer · Disposed 18,684 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F3: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.64 · Expires 2019-12-15 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-28 · Disposition to issuer · Disposed 24,000 · Balance 0 F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.79 · Expires 2020-12-31 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.43 · Expires 2022-12-17 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-09-28 · Disposition to issuer · Disposed 16,880 · Balance 0 F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.96 · Expires 2024-02-28 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-09-28 · Disposition to issuer · Disposed 11,740 · Balance 0 F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.85 · Expires 2024-10-31 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-09-28 · Disposition to issuer · Disposed 3,460 · Balance 0 F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $60.53 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2016-09-28 · Disposition to issuer · Disposed 13,560 · Balance 0 F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.50 · Expires 2025-09-30 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2016-09-28 · Disposition to issuer · Disposed 2,380 · Balance 0 F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.77 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2016-09-28 · Disposition to issuer · Disposed 38,530 · Balance 0 F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.45 · Expires 2026-04-08 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2016-09-28 · Disposition to issuer · Disposed 1,120 · Balance 0 F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-02-18 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2016-09-28 · Disposition to issuer · Disposed 14,474 · Balance 0 F5: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels. F6: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest)subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger. |
| Stock Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $11.60 · Expires 2022-01-03 | Direct | 0 |
Reported balance
After 2016-09-28 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2016-09-28 · Disposition to issuer · Disposed 58,800 · Balance 0 F7: This stock appreciation right (the "SAR") was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share base price of the SAR. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
F2: Includes 229 shares purchased through the Issuer's Employee Stock Purchase Plan on September 21, 2016.
F3: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger.
F4: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
F5: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels.
F6: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest)subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger.
F7: This stock appreciation right (the "SAR") was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share base price of the SAR.
Turning Point Therapeutics, Inc.
Report date August 17, 2022 · Filed August 17, 2022
Section 16 reporting ended · disclosed 2022-08-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 1
1 source rowRow 1 · 2022-08-17 · Disposition to issuer · Disposed 41,284 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount. F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law. F3: Includes 463 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.73 · Expires 2029-12-01 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 169,192 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $140.01 · Expires 2031-02-07 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Disposition to issuer · Disposed 29,175 · Balance 0 F5: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.68 · Expires 2032-02-08 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-17 · Disposition to issuer · Disposed 68,367 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount.
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law.
F3: Includes 463 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan.
F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.
F5: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2026 Filed Jun 15, 2026 21:23 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 38,040 | $0.00 Strike: $4.16 | $0.00 |
DisclosureSEC source: 0001654482-26-000003 · form4-06152026_090619.xml · derivative · entry 1 Hirmand Mohammad · CIK 0001654482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,040 Underlying: Common Stock · 38,040 shares Expires 2036-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:58 UTC | Whitehawk Therapeutics, Inc. WHWK · Entity 6074 | GrantStock Option (right to buy) · Derivative | 40,006 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001415889-25-017412 · form4-06162025_080632.xml · derivative · entry 1 Hirmand Mohammad · CIK 0001654482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,006 Underlying: Common Stock · 40,006 shares Expires 2035-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2025. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:10 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 45,832 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001415889-24-016872 · form4-06142024_080614.xml · derivative · entry 1 Hirmand Mohammad · CIK 0001654482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,832 Underlying: Common Stock · 45,832 shares Expires 2034-06-12 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2024. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 20:20 UTC | Whitehawk Therapeutics, Inc. AADI · Entity 6074 | GrantStock Option (right to buy) · Derivative | 59,206 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001209191-23-021531 · doc4.xml · derivative · entry 1 Hirmand Mohammad · CIK 0001654482 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,206 Underlying: Common Stock · 59,206 shares Expires 2033-03-27 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest on a monthly basis following the grant date on the same day of the month as the grant date (and if there is no corresponding day, on the last day of the month) such that all shares subject to option shall be fully vested on the three year anniversary of the grant date. The grant date is March 27, 2023. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 16:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 68,367 | Not disclosed Strike: $37.68 | Not disclosed |
DisclosureSEC source: 0001209191-22-046264 · doc4.xml · derivative · entry 4 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 68,367 shares Expires 2032-02-08 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 16:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 29,175 | Not disclosed Strike: $140.01 | Not disclosed |
DisclosureSEC source: 0001209191-22-046264 · doc4.xml · derivative · entry 3 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,175 shares Expires 2031-02-07 F5 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option. F5 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 16:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 169,192 | Not disclosed Strike: $54.73 | Not disclosed |
DisclosureSEC source: 0001209191-22-046264 · doc4.xml · derivative · entry 2 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 169,192 shares Expires 2029-12-01 F4 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F4 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 16:26 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerCommon Stock | 41,284 | $76.00 | $3,137,584.00 |
DisclosureSEC source: 0001209191-22-046264 · doc4.xml · nonDerivative · entry 1 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount. F2 · shares: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law. F3 · shares: Includes 463 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:08 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 68,367 | $0.00 Strike: $37.68 | $0.00 |
DisclosureSEC source: 0001209191-22-008980 · doc4.xml · derivative · entry 4 Hirmand Mohammad · CIK 0001654482 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,367 Underlying: Common Stock · 68,367 shares Expires 2032-02-08 F4 · derivative.exercise_date: 1/48th of the shares vest monthly following February 9, 2022. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:08 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008980 · doc4.xml · nonDerivative · entry 3 Hirmand Mohammad · CIK 0001654482 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,821 F3 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:08 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantCommon Stock | 18,983 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-008980 · doc4.xml · nonDerivative · entry 2 Hirmand Mohammad · CIK 0001654482 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,821 F3 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 18:08 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 669 | $36.30 | $24,284.70 |
DisclosureSEC source: 0001209191-22-008980 · doc4.xml · nonDerivative · entry 1 Hirmand Mohammad · CIK 0001654482 · EVP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,838 F1 · kind: Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021. F2 · balance_after: The Reporting Person acquired 301 shares on June 10, 2021 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 439 shares on December 10, 2021 pursuant to the ESPP. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 18:03 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 29,175 | $0.00 Strike: $140.01 | $0.00 |
DisclosureSEC source: 0001209191-21-009378 · doc4.xml · derivative · entry 2 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,175 Underlying: Common Stock · 29,175 shares Expires 2031-02-07 F2 · derivative.exercise_date: 1/48th of the shares vest monthly following February 8, 2021. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 18:03 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantCommon Stock | 6,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009378 · doc4.xml · nonDerivative · entry 1 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,767 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan. Read SEC document |
| January 05, 2021 Filed Jan 5, 2021 21:03 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 1,253 | $0.00 Strike: $54.73 | $0.00 |
DisclosureSEC source: 0001209191-21-001724 · doc4.xml · derivative · entry 7 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,192 Underlying: Common Stock · 1,253 shares Expires 2029-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F4 · derivative.exercise_date: 25% of the shares vest on December 2, 2020 and 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| January 05, 2021 Filed Jan 5, 2021 21:03 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 1,253 | $120.00 | $150,360.00 |
DisclosureSEC source: 0001209191-21-001724 · doc4.xml · nonDerivative · entry 5 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| January 05, 2021 Filed Jan 5, 2021 21:03 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 1,253 | $54.73 | $68,576.69 |
DisclosureSEC source: 0001209191-21-001724 · doc4.xml · nonDerivative · entry 4 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:03 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionStock Option (right to buy) · Derivative | 8,747 | $0.00 Strike: $54.73 | $0.00 |
DisclosureSEC source: 0001209191-21-001724 · doc4.xml · derivative · entry 6 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,445 Underlying: Common Stock · 8,747 shares Expires 2029-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F4 · derivative.exercise_date: 25% of the shares vest on December 2, 2020 and 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:03 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 8,747 | $120.42 | $1,053,313.74 |
DisclosureSEC source: 0001209191-21-001724 · doc4.xml · nonDerivative · entry 3 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F3 · price: The weighted average sale price for the transaction reported was $120.42, and the range of prices were between $120.00 and $121.00. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:03 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | SaleCommon Stock | 300 | $122.44 | $36,732.00 |
DisclosureSEC source: 0001209191-21-001724 · doc4.xml · nonDerivative · entry 2 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,031 F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 21:03 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Exercise / conversionCommon Stock | 8,747 | $54.73 | $478,723.31 |
DisclosureSEC source: 0001209191-21-001724 · doc4.xml · nonDerivative · entry 1 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 16, 2020. F2 · balance_after: The Reporting Person acquired 300 shares on June 12, 2020 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 284 shares on December 10, 2020 pursuant the ESPP. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 16:49 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 179,192 | $0.00 Strike: $54.73 | $0.00 |
DisclosureSEC source: 0001209191-19-058729 · doc4.xml · derivative · entry 1 Hirmand Mohammad · CIK 0001654482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,192 Underlying: Common Stock · 179,192 shares Expires 2029-12-01 F1 · derivative.exercise_date: 25% of the shares vest on December 2, 2020 and 1/48th of the shares vest monthly thereafter over the next three years. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerStock Appreciation Rights · Derivative | 58,800 | Not disclosed Strike: $11.60 | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · derivative · entry 13 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,800 shares Expires 2022-01-03 F7 · price: This stock appreciation right (the "SAR") was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share base price of the SAR. F7 · derivative.exercise_date: This stock appreciation right (the "SAR") was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share base price of the SAR. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerPerformance-Based Restricted Stock Units · Derivative | 14,474 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · derivative · entry 12 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,474 shares Expires 2020-02-18 F5 · shares: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels. F6 · price: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest)subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger. F6 · derivative.exercise_date: The PSUs were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such PSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest)subject to any required withholding of taxes. In connection with the Merger, vesting of the PSUs was accelerated and the PSUs became fully vested effective immediately prior to the effective time of the Merger. F5 · derivative.underlying_shares: The number of shares subject to the performance-based restricted stock unit (the "PSUs") is based on deemed satisfaction of all applicable performance goals at the maximum levels. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 1,120 | Not disclosed Strike: $46.45 | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · derivative · entry 11 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,120 shares Expires 2026-04-08 F4 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 38,530 | Not disclosed Strike: $35.77 | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · derivative · entry 10 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,530 shares Expires 2026-02-28 F4 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 2,380 | Not disclosed Strike: $42.50 | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · derivative · entry 9 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,380 shares Expires 2025-09-30 F4 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 13,560 | Not disclosed Strike: $60.53 | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · derivative · entry 8 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,560 shares Expires 2025-03-02 F4 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 3,460 | Not disclosed Strike: $52.85 | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · derivative · entry 7 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,460 shares Expires 2024-10-31 F4 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 11,740 | Not disclosed Strike: $35.96 | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · derivative · entry 6 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,740 shares Expires 2024-02-28 F4 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 16,880 | Not disclosed Strike: $27.43 | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · derivative · entry 5 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,880 shares Expires 2022-12-17 F4 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 60,000 | Not disclosed Strike: $3.79 | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · derivative · entry 4 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2020-12-31 F4 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 24,000 | Not disclosed Strike: $8.64 | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · derivative · entry 3 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2019-12-15 F4 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F4 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Disposition to issuerCommon Stock | 18,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · nonDerivative · entry 2 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F3 · shares: Represents unvested restricted stock units (the "RSUs") that were cancelled in the Merger and, in lieu of any issuance of shares in settlement of such RSUs, converted into the right to receive cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes. In connection with the Merger, vesting of the RSUs was accelerated and the RSUs became fully vested effective immediately prior to the effective time of the Merger. F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. Read SEC document |
| September 28, 2016 Filed Sep 30, 2016 17:44 UTC | MEDIVATION, INC. MDVN · Entity 181987 | OtherCommon Stock | 39,068 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-143378 · doc4.xml · nonDerivative · entry 1 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2 · shares: Includes 229 shares purchased through the Issuer's Employee Stock Purchase Plan on September 21, 2016. F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 16:50 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,940 | $0.00 Strike: $4.69 | $0.00 |
DisclosureSEC source: 0001209191-16-142002 · doc4.xml · derivative · entry 4 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,940 shares Expires 2018-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 16:50 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,620 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001209191-16-142002 · doc4.xml · derivative · entry 3 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,620 shares Expires 2018-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 16:50 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Exercise / conversionCommon Stock | 11,940 | $4.69 | $56,028.45 |
DisclosureSEC source: 0001209191-16-142002 · doc4.xml · nonDerivative · entry 2 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 16:50 UTC | MEDIVATION, INC. MDVN · Entity 181987 | Exercise / conversionCommon Stock | 5,620 | $4.00 | $22,494.05 |
DisclosureSEC source: 0001209191-16-142002 · doc4.xml · nonDerivative · entry 1 Hirmand Mohammad · CIK 0001654482 · Interim Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.